a·lac·ri·ty [uh-lak-ri-tee] cheerful readiness, promptness, or willingness
Europe: London BioScience Innovation Centre 2 Royal College Street London NW1 0NH
USA: Cambridge Innovation Center 1 Broadway, 14th Floor Kendall Square, Cambridge MA 02142

Case Studies

Neuroscience Due Diligence

Our expert neuroscience consultants have helped several clients with due diligence of new CNS drug development opportunities…

Read more »

Cancer clinical development strategy

Alacrita’s expert medical team provides medical advisory services including clinical development strategy and operational Chief Medical Officer support…

Read more »

AAV Gene Therapy Consulting

Alacrita conducted an assessment of an AAV gene therapy for an ophthalmic indication, focusing on market potential, technical and regulatory issues and identification of key risks…

Read more »

Clinical strategy, medical oversight and clinical due diligence

Alacrita supports several companies with medical and clinical strategy advice and support. We have particular depth in oncology, but also have expertise in infectious diseases (in particular novel antibiotics), autoimmune and respiratory diseases…

Read more »

Ex-US diagnostics business development strategy

Alacrita’s diagnostics consultants were tasked with developing an ex-US business development strategy and identifying sources of non-dilutive finance for a well-funded venture capital funded diagnostics company.

Read more »

Expert report

Alacrita draws upon broad and deep, often highly specialized, expertise within its network of over 350 consultants. We prepare authoritative expert reports on behalf of companies in support of their regulatory submissions or commercial negotiations.

Read more »

Valuation and Deal Support

Alacrita uses a Monte Carlo simulation methodology to model ranges of key inputs, thereby capturing inherent uncertainties, allowing the rNPV to be calculated as a range of possibilities and identifying the assumptions with the greatest impact on deal value…

Read more »

Transatlantic payer research and strategic market access

For an emerging specialty pharma company facing an urgent partnering transaction deadline, Alacrita’s strategic market access consultants conducted a series of payer interviews across the USA and EU3

Read more »

Life Science Due Diligence

Alacrita’s due diligence team is led by a senior pharmaceutical executive who conducted over 300 due diligence exercises whilst responsible for Business Development and Licensing at a big pharma. He is supported by a team of specialists who have substantial experience of conducting due diligence; this expertise regularly deployed to support financial investment and licensing decisions. Some selected examples are detailed…

Read more »

EU payer research to inform Phase 3 design

A Cambridge MA based therapeutics company asked Alacrita to provide feedback on the Phase III protocol design for its lead drug, specifically from an EU payer perspective. Alacrita’s expert European payer consultants worked with the company to determine to what extent the protocol was likely to generate data European payers would be looking for

Read more »

Life Science Technology Scouting

Alacrita supports a number of pharma, biotech and life science companies in searching for acquisition and partnering opportunities…

Read more »

R&D strategy in radiopharmaceuticals

Alacrita developed an R&D strategy for a major nuclear physics research institute looking to build a capability in nuclear medicine…

Read more »

Medical Device Consulting

Alacrita’s medtech consultants work across a broad range of medical devices and technologies, with projects spanning regulatory and supply chain support through to payer research, due diligence and commercial planning

Read more »

Due diligence - regulatory affairs

To help a clinical stage biopharmaceutical specialist company in its regulatory due diligence activities, Alacrita assembled an expert team comprising an ex-quality assessor who had previously worked in the biologicals unit at the MHRA (primarily on EMA centralised procedures), and an ex-Senior Director and ex-Medical Advisor for a biotechnology company

Read more »

University IP portfolio triage

Working with King’s College London, Alacrita helped to evaluate and prioritize life science research projects for funding and commercial support with the objective to help promising intellectual property attract and secure investor and partner interest

Read more »

Cancer immunotherapy consulting

Alacrita has advised a number of cancer immunotherapy companies on a diverse range of projects. Examples include valuation models to support partnering discussions for a highly potent autologous cell-based cancer immunotherapy, through to clinical strategy advice for a company developing a peptide-based approach.

Read more »

Business Development and Partnering Support

Alacrita provides opportunity assessment, valuation and deal structure support to both in-licensors and out-licensors. We work alongside in-house licensing and business development professionals providing real world experience and data upon which to base critical transaction decisions…

Read more »

Payer research and pricing assessment

Alacrita was asked to assess the market opportunity for a novel anaemia therapy in order to facilitate discussions with potential partners

Read more »

ISO13485 Audit by medical device consultant

Alacrita was asked by a blue chip healthcare consumer products company to provide a medical device consultant to conduct an ISO134854 audit of the mainland Europe manufacturing site of a potential supplier company…

Read more »

Regulatory Affairs: BLA submission support

Alacrita’s regulatory team provided expert BLA and MAA submission advice and support to a pharma client preparing for approval of its first biologic…

Read more »

Medical Imaging

Our Medical Imaging consulting practice is led by a recognized expert in medical imaging with over 25 years of experience pharmaceutical, device and biopharmaceutical services organizations.

Read more »

oncology project plan

Alacrita was requested by the technology transfer function of a leading cancer research institute to produce a development plan for a very promising small molecule lead series against a novel anti-invasion/anti-metastasis target for solid tumours…

Read more »

Transatlantic payer research - pain therapy

A pharmaceutical company asked Alacrita to assist in providing an HTA/payer perspective on the proposed label and mechanism of action/clinical positioning for its pain drug, to ensure that the Phase II/III trials were optimally designed…

Read more »

Antibodies

Alacrita has substantial expertise in antibody discovery, development and commercialisation. We have helped a number of clients assess antibody opportunities, including target and technology assessment, strategic valuation and biosimilar market positioning…

Read more »

Diagnostics due diligence

On behalf of a major European venture capital investor, Alacrita reviewed the business plan and competitive positioning of a novel point-of-care diagnostics company. The company was developing a fully integrated point of care diagnostic instrument platform to enable sensitive and fast tests in the ICU/ER/OR…

Read more »

Intellectual Property Analysis & Strategy

Alacrita’s IP Practice provides analysis, assessment and advice on life science IP. The practice is focussed on both helping clients extract maximum value from their IP portfolios and supporting companies and investors conducting IP due diligence…

Read more »

Observer on BoD for private equity investor

On behalf of a private equity (PE) investor, an Alacrita partner was retained as an observer on the board of a regenerative medicine/advanced wound healing company where he contributed to BoD discussions based on his industry expertise and strategic understanding gained through a long association with companies in similar stages of development.

Read more »

Start-up support and funding

Alacrita worked with the CEO and Chairman of a start-up biotech company to secure a successful Series A financing. Alacrita developed a rational development strategy for Evgen’s novel oncology compound, delivered an expert toxicology report and acted as a ‘technical champion’ during investor presentations…

Read more »

Radiopharmaceuticals

For a major public/private investor in a BRIC territory, Alacrita advised on investment strategy for building radiopharmaceutical infrastructure and capacity in the investor’s home country, along with an international M&A strategy.

Read more »

Strategy for biomarker identification technology

Alacrita’s antibody consultants were engaged to help a start-up company that had developed a suite of proprietary antibody technologies to identify accessible cell surface proteins for discovery of candidate therapeutic mAb targets and/or biomarkers…

Read more »

Feasibility study - ophthalmic therapies

A leading research institute developing novel approaches for production of ophthalmic treatments asked Alacrita to conduct a market and competitive assessment of the current supplier base and prospective novel technological approaches

Read more »

Operational Support

Alacrita provides hands-on support to life science organisations where a full-time appointment cannot be justifed. Examples include oncology project management, vaccine product development and in-licensing support…

Read more »

Payer Advisory Board

For a US company looking to understand how UK payers would view their technology, Alacrita conducted desk research to develop the technology’s value proposition and then convened a payer advisory board…

Read more »

Monoclonal antibodies to treat bacterial infections

Alacrita’s antibody consultants conducted a review of the potential of modern antibody technologies to treat severe bacterial infections. Alacrita detailed the challenges involved, the types of target available and conducted a review of the industry’s antibody pipeline. We conducted a SWOT analysis on monoclonal antibody technologies that the client had encountered with respect to their applicability to bacterial infections, with suggestions of other technologies that the company should consider.

Read more »

Opportunity analysis - blood products

A life science venture capital fund was contemplating investing in advanced plasma product opportunities being developed by a biopharmaceutical company. Alacrita was commissioned to provide a reality check on the commercial opportunities on offer

Read more »

510(k) consulting for respiratory medical device

Alacrita’s 501(k) regulatory affairs specialist supported a UK medical device company secure 510(k) clearance from FDA for a respiratory measurement device

Read more »

GMP facility - feasibility study for biologics production

Drawing on expertise from its regulatory, gene therapy and manufacturing consultants, Alacrita conducted feasibility study and formulated a business case for a new GMP facility for production of investigational therapies

Read more »

Wound care - regulatory support

A world-leading manufacturer of wound care products was assessing opportunities in advanced wound care, and as part of the survey was looking at regulatory pathways that pertained to various classes of product

Read more »

Life Science Professional Employer Organization

For non-US life science companies looking to employ a worker in the US, Alacrita acts as the employer of record and takes on employee management tasks…

Read more »

Novel Antibody Screening Technology

Alacrita’s antibody consultants were asked to help assess the market potential and develop a commercialization strategy for a novel antibody discovery and screening platform. The client had developed a novel antibody technology capable of rapidly screening and selecting millions (and potentially billions) of antibody producing clones using a simple array technology, allowing the analysis of every single clone without the need for enrichment…

Read more »

Medical device technology assessment

A university research team had worked for a number of years on the development of a novel interventional cardiology device. Alacrita was asked to provide a reality check on the status of the project, including current activities and a top level sanity check on its technical feasibility

Read more »

Dental products business strategy review

A dental products company called upon Alacrita’s expertise to review its business strategy. For this particular assignment Alacrita deployed one of its senior dental industry executives with broad experience transforming both Fortune 500 global brands and entrepreneurial ventures

Read more »

Wound care - exit planning

A company developing a novel wound care product was embarking on a significant clinical trial programme. Being hopeful of a positive outcome from the clinical trial programme, the client was planning an investor exit in the coming 24 months and therefore wanted to connect with potential acquirers prior to moving on to deal execution.

Read more »